¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"target plasma"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • fresh frozen plasma
    ½Å¼±³Ãµ¿Ç÷Àå
  • human plasma protein fraction
    »ç¶÷Ç÷Àå´Ü¹éºÐÀ²
  • interstitial plasma cell pneumonia
    »çÀÌÁúÇüÁú¼¼Æ÷Æó·Å, ÆóÆ÷ÀÚÃæÁõ
  • normal human plasma
    Á¤»ó»ç¶÷Ç÷Àå
  • plasma
    1. Ç÷Àå 2. ¿øÇüÁú, ¼¼Æ÷Áú
  • plasma cell
    ÇüÁú¼¼Æ÷
  • plasma cell dyscrasia
    ÇüÁú¼¼Æ÷Áúȯ
  • plasma cell granuloma
    ÇüÁú¼¼Æ÷À°¾ÆÁ¾
  • plasma cell mastitis
    ÇüÁú¼¼Æ÷À¯¹æ¿°
  • plasma cell myeloma
    ÇüÁú¼¼Æ÷°ñ¼öÁ¾
  • plasma coagulase
    Ç÷ÀåÀÀ°íÈ¿¼Ò
  • plasma coagulation factor
    Ç÷ÀåÀÀ°íÀÎÀÚ
  • plasma component transfusion
    Ç÷À强ºÐ¼öÇ÷
  • plasma cross matching
    Ç÷Àå±³Â÷½ÃÇè
  • plasma exchange
    Ç÷À屳ȯ(¼ú)
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • antihemophilic plasma
    Ç×Ç÷¿ìº´Ç÷Àå
  • blood plasma
    Ç÷Àå
  • plasma cell
    ÇüÁú¼¼Æ÷
  • plasma coagulase
    Ç÷ÀåÀÀ°íÈ¿¼Ò
  • thromboplastin plasma component
    Æ®·Òº¸ÇÃ¶ó½ºÆ¾Ç÷À强ºÐ
  • plasma cell dyscrasia
    ÇüÁú¼¼Æ÷Áúȯ
  • effective renal plasma flow
    À¯È¿ÄáÆÏÇ÷Àå·ù·®
  • plasma exchange
    Ç÷À屳ȯ, Ç÷À屳ȯ¼ú
  • plasma volume expander
    ÀΰøÇ÷ÀåÁõ·®Á¦
  • plasma coagulation factor
    Ç÷ÀåÀÀ°íÀÎÀÚ
  • plasma thromboplastin factor
    Ç÷À寮·Òº¸ÇÃ¶ó½ºÆ¾ÀÎÀÚ
  • plasma cell granuloma
    ÇüÁú¼¼Æ÷À°¾ÆÁ¾
  • plasma hemoglobin
    Ç÷ÀåÇ÷¾×¼Ò
  • plasma iron
    Ç÷Àåö
  • plasma membrane
    ÇüÁú¸·
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • plasma cell
    ÇüÁú(û¡òõ)¼¼Æ÷
  • plasma cell
    ÇüÁú¼¼Æ÷(û¡òõá¬øà).
  • plasma cell
    ÇüÁú¼¼Æ÷
  • plasma cell
    ÇüÁú¼¼Æ÷
  • plasma cell dyscrasia
    ÇüÁú¼¼Æ÷ÀÌȥȭÁõ
  • plasma cell dyscrasia
    ÇüÁú¼¼Æ÷Áúȯ(û¡òõá¬øàòðü´), ÇüÁú¼¼Æ÷Àå¾Ö(¡­î¡äô), ÇüÁú¼¼Æ÷ÀÌȥȭÁõ(¡­ì¶ûèûúñø)
  • plasma cell gingivostomatitis
    ÇüÁú¼¼Æ÷ Ä¡Àº ±¸³»¿°
  • plasma cell leukemia
    ÇüÁú¼¼Æ÷¼º ¹éÇ÷º´
  • plasma cell leukemia
    ÇüÁú¼¼Æ÷¼º ¹éÇ÷º´(û¡òõá¬øààõ ÛÜúìÜ»)
  • plasma cell leukemia
    ÇüÁú¼¼Æ÷ ¹éÇ÷º´
  • plasma cell mastitis
    ÇüÁú¼¼Æ÷¼ºÀ¯¹æ¿°(û¡òõá¬øààõêáÛ®æú)
  • plasma cell myeloma
    ÇüÁú¼¼Æ÷ °ñ¼öÁ¾
  • plasma cell myeloma
    ÇüÁú¼¼Æ÷°ñ¼öÁ¾(û¡òõá¬øàÍéâÐðþ)
  • plasma cell pneumonia
    ÇüÁú¼¼Æ÷¼º Æó·Å.
  • plasma cell pneumonia
    ÇüÁú¼¼Æ÷¼ºÆó·Å(û¡òõá¬øààõøËæú)
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • single target multi-hit model
    ´ÜÀÏÇ¥Àû´Ù¹ßÀûÁß ¸ðµ¨
  • source-target distance, STD
    ¼±¿øÇ¥Àû°£°Å¸®
  • target
    Ç¥Àû(øöîÜ)
  • target cell
    Ç¥Àû¼¼Æ÷
  • target cell anemia
    Ç¥ÀûÀûÇ÷±¸¼º ºóÇ÷(øöîÜ îåúìϹàõÞ¸úì).
  • target cell anemia
    Ç¥ÀûÀûÇ÷?úÔºóÇ÷(øöîÜ îåúìϹàõÞ¸úì)
  • target configuration
    °ú³á ¸ð¾ç (Ç¥Àû¸ð¾ç)
  • target configuration
    °ú³á ¸ð¾ç (Ù¼åÆ)
  • target glands
    Ç¥Àû¼±(øöîÜàÍ).
  • target lesion
    Ç¥Àû º´º¯
  • target lesions
    Ç¥Àûº´¼Ò, °ú³áº´¼Ò, ŸÄÉÆ®º´¼Ò
  • target organ
    Ç¥ÀûÀå±â
  • target pattern
    °ú³á ¾ç»ó
  • target sign
    °ú³á ¡ÈÄ
  • target skin distance radiation
    Ç¥ÀûÇǺΰŸ®¹æ»ç¼±
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 12 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • plasma sol
    Á¹»ó(ßÓ) ¿øÇüÁú(ê«û¡òõ)
  • plasma-specific enzyme
    Ç÷À寝ÀÌ È¿¼Ò(úìíì÷åì¶ý£áÈ)
  • plasma thromboplastic factor
    Ç÷Àå Ç÷ÀüÇü¼ºÀÎÀÚ(úìíìúìîûû¡à÷ì×í­)
  • plasma thromboplastic factor B
    Ç÷Àå Ç÷ÀüÇü¼ºÀÎÀÚ B
  • plasma thromboplastin antecedent
    Ç÷Àå(úìíì) Æ®·Òº¸ÇÃ¶ó½ºÆ¾ Àü±¸¹°(îñÏÌÚª)
  • plasma thromboplastin component
    Ç÷Àå(úìíì) Æ®·Òº¸ÇÃ¶ó½ºÆ¾ ¼ººÐ(à÷ÝÂ)
  • plasma transferrin
    Ç÷Àå(úìíì) Æ®¶õ½ºÆä¸°
  • plasma transglutaminase
    Ç÷Àå(úìíì) Æ®¶õ½º±Û·çŸ¹Ì³×À̽º
  • separated plasma
    ºÐ¸®Ç÷Àå(ÝÂ×îúìíì)
  • sex steroid binding plasma protein
    ¼º(àõ)½ºÅ×·ÎÀÌµå °áÇÕ(Ì¿ùê) Ç÷Àå(úìíì) ´Ü¹éÁú(úìíìÓ±ÛÜòõ)
  • true plasma
    ¼øÇ÷Àå(âíúìíì)
  • whole plasma
    ÀüÇ÷Àå(îïúìíì)
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
MLTI mixed lymphocyte target interaction
MTI malignant teratoma, intermediate; minimum time interval; moving target indicator
NTE neuropathy target esterase; neurotoxic esterase; not to exceed
OTC ornithine transcarbamylase; oval target cell; over-the-counter; oxytetracycline
PTV planning target volume; posterior tibial vein
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
TCI Target Controlled Infusion
TH Target height
TLR Target lesion revascularization
TOD Target organ damage
TVR Target vessel revascularization
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • plasma cell dyscrasia
    Ç÷Àå ¼¼Æ÷ ÀÌ»ó
  • plasma cell pneumonia
    ÇüÁú ¼¼Æ÷¼º Æó·Å
  • plasma cloud
    Çö󽺸¶ ±¸¸§
  • plasma cortisol
    Ç÷Àå ÄÚÆ¼Á¹
  • plasma extravasation
    Ç÷Àå À¯Ãâ, Ç÷Àå ÀÏÇ÷
  • plasma formation
    Çö󽺸¶ Çü¼º
  • plasma hemoglobin
    Ç÷Àå Çì¸ð±Û·Îºó, Ç÷Àå Ç÷¾×¼Ò
  • plasma membrane
    ¿øÇüÁú ¸·, ¼¼Æ÷ ÇüÁú¸·
    ¿øÇüÁú Ç¥¸éÀ» µ¤´Â ¿¯Àº ¸·. µÎ²²´Â 5¡­25 ¥ìmÀÌ´Ù. ±¤ÇÐÇö¹Ì°æÀ¸·Î´Â °üÂûÇÒ ¼ö ¾øÁö¸¸ ÀüÀÚÇö¹Ì°æÀ¸·Î °üÂûÀÌ °¡´ÉÇÏ´Ù. ÀÌ ¸·Àº ¿øÇüÁú Ç¥¸é, Áï ¸Å¾×°úÀÇ °è¸é¿¡ Çü¼ºµÈ ÈíÂø¸· ¶Ç´Â ħÀü¸·À¸·Î »ý°¢µÈ´Ù. ¿øÇüÁú ¸·ÀÇ ºÐÀÚ ±¸Á¶´Â ·¹½ÃƾÀ̳ª ÄÝ·¹½ºÅ×·Ñ µîÀÇ Ç¥¸é Ȱ¼º ¹°Áú ºÐÀÚ°¡ 2ºÐÀÚ ÃþÀ¸·Î ±× Ç¥¸é¿¡ ¹è¿­µÇ¸ç, À̰ÍÀ» °¢ 1ºÐÀÚ ÃþÀÇ ´Ü¹éÁú ºÐÀÚ°¡ ¾çÂÊ¿¡¼­ »÷µåÀ§Ä¡ÇÑ ´ÜÀ§¸· ±¸Á¶ÀÌ´Ù. ÀüÀÚÇö¹Ì°æÀûÀ¸·Î ÀÌ ´ÜÀ§´Â ¾Ï, ¸í, ¾ÏÀÇ 3Ãþ
  • plasma protein
    Ç÷Àå ´Ü¹é, Ç÷Àå ´Ü¹éÁú
    1. Ç÷Àå¿¡ Á¸ÀçÇÏ´Â ¿©·¯ Á¾·ùÀÇ ´Ü¹éÁú. ¿î¹Ý ´Ü¹éÁú
  • plasma protein binding
    Ç÷Àå ´Ü¹é °áÇÕ
  • plasma prothrombin time
    Ç÷Àå ÇÁ·ÎÆ®·Òºó ½Ã°£
  • plasma substitute
    Ç÷Àå ´ë¿ëÁ¦
  • plasma thromboplastin antecedent deficiency
    PTA °áÇÌÁõ
  • pooled plasma
    È¥ÁÖ Ç÷Àå
  • renal plasma flow
    ½Å Ç÷Àå·ù, ½Å Ç÷Àå·ù·®
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
beam-plasma reaction <radiobiology> Fusion reaction which occurs from the collision of a fast beam ion with a thermal plasma ion.
(09 Oct 1997)
bean-shaped plasma <radiobiology> A toroidal plasma indented on the inboard side (the side with the donut hole), that results in additional stability to ballooning modes. Moderate indentation may provide access to the second-stability region (high beta).
(13 Nov 1997)
blood plasma <haematology> Acellular fluid in which blood cells are suspended. Serum obtained by defibrinating plasma (plasma derived serum) lacks platelet released factors and is less suitable to support the growth of cells in culture.
(13 Oct 1997)
blood plasma fractions Portions of the blood plasma as separated by electrophoresis or other technique.
(05 Mar 2000)
rapid plasma reagin <investigation> The rapid plasma reagin test is similar to the VDRL test for diagnosing syphilis. This blood test is designed to detect an antibody substance in the bloodstream when syphilis infection is present. Early syphilis infections may be RPR negative.
See: VDRL
(17 Dec 1997)
rapid plasma reagin test A group of serologic test's for syphilis in which unheated serum or plasma is reacted with a standard test antigen containing charcoal particles; positive test's yield a flocculation. A modification, called the RPR (circle) card test, is widely used as a screening test.
Synonym: RPR test.
(05 Mar 2000)
renal plasma flow <physiology> The amount of plasma that perfuses the kidneys per unit time, approximately 10% greater than effective renal plasma flow.
It should be differentiated from the renal blood flow which refers to the total volume of blood flowing through the renal vasculature, while the renal plasma flow refers to the rate of plasma flow.
(12 Dec 1998)
peak plasma drug concentration <pharmacology> The highest level of drug that can be obtained in the blood usually following multiple doses.
(09 Oct 1997)
granuloma, plasma cell A slow-growing benign pseudotumour in which plasma cells greatly outnumber the inflammatory cells.
(12 Dec 1998)
granuloma, plasma cell, orbital A distinctive, chronic inflammatory reaction in the orbital tissues of the eye, of unknown aetiology, that may closely resemble a neoplasm and often becomes bilateral. Symptoms include exophthalmos and congestion of the lids with oedema. When limitation of ocular motility also occurs, it is sometimes called orbital myositis.
(12 Dec 1998)
granuloma, plasma cell, pulmonary A pseudotumour of the lung composed of inflammatory cells and showing complete maturity of fibroblastic components with a striking lack of mitosis. It is also called postinflammatory pseudotumour and pseudoneoplastic pneumonitis. (berardi, r.s. Et al. Inflammatory pseudotumours of the lung. Surg gynecol obstet 156:89-96, jan 83)
(12 Dec 1998)
collisionless plasma model <radiobiology> Model of a plasma in which the density is so low, or the temperature so high, that close binary (two-body) collisions have practically no significance (on certain timescales) because the time scales of interest are shorter than the collision time. Yields valid physical results for timescales much shorter than the average collision time in a real plasma.
(09 Oct 1997)
plasma <haematology> Acellular fluid in which blood cells are suspended. Serum obtained by defibrinating plasma (plasma derived serum) lacks platelet released factors and is less suitable to support the growth of cells in culture.
(13 Oct 1997)
plasma accelerator globulin <chemical> Heat- and storage-labile plasma glycoprotein which accelerates the conversion of prothrombin to thrombin in blood coagulation. Factor v accomplishes this by forming a complex with factor xa, phospholipid, and calcium (prothrombinase complex). Deficiency of factor v leads to owren's disease.
Chemical name: Blood-coagulation factor V
(12 Dec 1998)
plasma albumin <protein> The serum level of the low molecular protein albumin. Albumin, produced by the liver, plays an important role in maintaining plasma oncotic pressure. Normal serum albumin should be 3.5-5.0 grams per decilitre. Low serum albumin can be found in cases of liver disease and malnutrition.
(27 Sep 1997)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
ÅëÇÕ°Ë»ö ¿Ï·á